Cord Blood America Inc. (CBAI.OB)

Posted: Thu Jul 12, 2007 10:50 am

Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children.

The company's mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

For more information please visit: http://www.qualitystocks.net/clients.php?clientid=cordblood#head
Blog: http://blog.qualitystocks.net/?cat=52

Posted: Fri Jul 13, 2007 3:21 pm

Cord Blood America Inc. (CBAI.OB) Salutes Study Validating Insulin Generation from Umbilical Cord Blood

Cord Blood America, Inc. (CBAI.OB), reports that researchers at the University of Texas Medical Branch at Galveston who announced, in Science Daily, that they have engineered adult stem cells from human umbilical cord blood to produce insulin.

This fundamental discovery could help cure type I diabetes by allowing people to grow their own insulin-producing cells for a damaged or defective pancreas, the Texas researchers said.

“Diabetes is a far more common affliction than cancer and leukemia, traditionally treated with stem cells,” said Matthew Schissler, Cord Blood America CEO. “The progress with stem cells to treat Type I diabetes may logically grow our potential customer base exponentially.”

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:21 pm

Cord Blood America, Inc. (CBAI.OB) Evaluates Alternative Ways to Unlock Value for its Subsidiaries

Cord Blood America announced today that it has signed a consulting agreement with Midtown Partners & Co., LLC to find ways to unlock value for its subsidiaries.

Matthew Schissler, Cord Blood America Chairman and CEO, stated, “Management sees this opportunity as a significant step forward in Cord Blood America’s overall business plan. Management has worked diligently to line up this milestone opportunity, which could entirely fund the parent Company’s future growth.”

The Senior Vice President at Midtown Parners commented on Cord Blood as being valuable, but doesn’t have the same attention other companies have in the public markets. He commented, “Cord Blood America has some of the best financial numbers in the sector, yet has not achieved the name recognition deserved in the stem cell arena. We want to improve the street perception of the company and do it quickly by identifying the best strategic alternatives for the company and its subsidiaries.”

The capital required to fund the transaction will be funded entirely from finances made available through the new transaction. It is the company’s mission to continue with accretive acquisitions, strategic organic growth and to improve the balance sheet.

In closing, Mr. Schissler stated, “This process should allow the company to realize its full potential.”

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:22 pm

Cord Blood America, Inc. (CBAI.OB) CEO Updates Shareholders on Latest Progress

Matthew Schissler, CEO of Cord Blood America, addressed the shareholders concerning the company’s latest progress. He stated, “I am 100% confident in the ability of CBAI to continue to grow, thrive and be a leader in the stem cell storage industry. I am also extremely excited about the current and future prospects of the organization, and have never felt better about the direction of our Company.”

Cord Blood is very pleased with its many accomplishments. They have lowered operational loss, increased revenues, and halved the basic and diluted loss per share. In the second quarter, the company announced record revenues of $1.7 million and a gross profit for the first three months of the year of almost $599,259.

Earlier this year, the company promised to be aggressive in finding accretive acquisitions, but is also growing organically by using a sales model connected to health insurance provider channels. Cord Blood has assured investors that they are making every effort to become cash flow positive through such strategies as accretive assets, by reducing costs, and by focusing on strategic growth.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:22 pm

Cord Blood America, Inc. (CBAI.OB) Announces a New Addition to the Board of Directors

Cord Blood America announced this morning that Richard J. Neeson will join the company’s Board of Directors. He brings extensive knowledge and expertise which will assist him in his primary responsibility of negotiating acquisitions, joint ventures and strategic partnerships.

In 1993 he joined Independence Blue Cross as President and Chief Operating Officer, and today the company is Philadelphia’s largest heal insurer with 3.4 million clients and employs nearly 9,500 people.

Mr. Neeson stated, “The importance of umbilical cord blood collection is becoming better known every day and we feel the strong obligation to continue to let expectant parents become aware of this unique medical resource. I am pleased by this opportunity to serve a company in the life-saving business.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:22 pm

Independence Blue Cross of Pennsylvania Executive Named to Board of Cord Blood America Inc. (CBAI.OB)

Cord Blood America, Inc. (CBAI.OB) reports that Richard J. Neeson, Senior Vice President of Independence Blue Cross, Philadelphia, Pa., and President and Chief Executive Officer of NewSeasons, a subsidiary, has been named to its Board of Directors.

“Mr. Neeson is primarily responsible for acquisitions, joint ventures and strategic partnerships, including negotiation, contract development and oversight at Independence Blue Cross, and this experience and expertise will prove invaluable for the growth through acquisitions of Cord Blood America,” said Matthew Schissler, CEO.

Independence Blue Cross and its subsidiaries are the Philadelphia region’s largest health insurers with more than 2.6 million members locally, and 3.4 million overall. It employs nearly 9,500 people and annually process more than 32 million claims. It serves all areas of the health care market by offering quality products and services such as Managed Care, Traditional Indemnity, Medicare, and Medicaid.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:23 pm

Cord Blood America, Inc. (CBAI.OB) Continues with its Plans to Reduce Debt

Cord Blood America, a company which is focused on brining the life saving potential of stem cells to families internationally, announced that the family of the Chief Executive Officer has loaned the company $223,500 to reduce its debt.

Matthew Schissler, CEO of Cord Blood America, stated, “Putting money into the Company provides it the short term working capital it needs, something that doesn’t occur if this discretionary money were spent instead on purchasing stock on the open market. This investment gives us the opportunity to focus on the long term growth.”

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:23 pm

Debt Reduction is Key Priority for Cord Blood America Inc. (CBAI.OB)

Cord Blood America, Inc. (CBAI.OB) reports that the family of Matthew Schissler, CEO, has loaned the Company $223,500, through an arrangement involving a third party, to reduce debt.

“Putting money into the Company provides it the short term working capital it needs, something that doesn’t occur if this discretionary money were spent instead on purchasing stock on the open market,” Mr. Schissler said. “This investment gives us the opportunity to focus on the long term growth.”

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children.

Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:23 pm

Cord Blood America, Inc. (CBAI.OB) Appears on Money TV

Cord Blood America announced that its CEO, Matthew Schissler, was featured on MoneyTV. The television program is all about money and provides insight into companies by interviewing CEOs.

Matthew Schissler discussed the company’s umbilical cord blood and stem cell storage business, the recent veto of the embryonic stell cell research bill by President Bush, and the company’s efforts to reduce debt.

The CEO stated earlier, “I am 100% confident in the ability of CBAI to continue to grow, thrive and be a leader in the stem cell storage industry. I am also extremely excited about the current and future prospects of the organization, and have never felt better about the direction of our Company.”

The important blood is saved to treat certain diseases such as heart disease, Parkinson’s disease, spinal cord injuries, sickle cell anemia, Multiple Sclerosis and other difficult diseases. Researchers believe that these stem cells can someday be turned into any tissue in the body, which could repair a damaged hear or assist in recovering from a stroke.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:32 pm

Cord Blood America, Inc. (CBAI.OB) Retires $650,000 of Registered Convertible Debt

Cord Blood America was pleased to announce this morning that $650,000 of convertible debt has been retired.

Matthew Schissler, CEO of Cord Blood, stated, “’Since the January 25, 2007 Effective Registration statement the holders of this convertible debt have been selling our common stock. We are well aware that this has been a significant drag on the market and we are grateful for our many investors who have patiently waited through this difficult period. We have confirmed that the holders of the debt have converted all their U.S. Securities & Exchange Commission registered debt as of June 28, 2007.”

He continued to say that the retirement is a major milestone, and the company intends to service future debts with cash flow from existing business or with an acquisition.

In conclusion he stated, “We are focused on growing the business through organic growth, accretive acquisitions, and intelligent management, with the goal of becoming cash flow positive and continually improving the balance sheet.”

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:32 pm

Cord Blood America, Inc. (CBAI.OB) Focuses on Becoming Cash Flow Positive

Cord Blood is focused on continually improving the balance sheet and becoming cash flow positive. Recently, the company retired $650,000 of Registered Convertible Debt to meet its goals.

The CEO of Cord Blood stated, “This is a major milestone for Cord Blood America. As we have previously stated, we intend that new debts will be serviced by cash flow from existing business or from an acquisition. We are focused on growing the business through organic growth, accretive acquisitions, and intelligent management, with the goal of becoming cash flow positive and continually improving the balance sheet.

The company has also taken other steps to meet its goal such as lower operational loss, increase revenue, and halve the basic and diluted loss per share.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:32 pm

Cord Blood America (CBAI.OB) Retired Convertible Debt

Cord Blood America, Inc. (CBAI.OB) previously announced that $650,000 of convertible debt was retired.

Matthew Schissler, CEO of CBAI, stated that “Since the January 25, 2007, Effective Registration statement the holders of this convertible debt have been selling our common stock”. The CEO further stated “We are well aware that this has been a significant drag on the market and we are grateful for our many investors who have patiently waited through this difficult period. We have confirmed that the holders of the debt have converted all their U.S. Securities & Exchange Commission registered debt as of June 28, 2007.”

Mr. Schissler firmly discussed that all future debt will be served by cash flow from their direct business’s actions or cash flow through an acquisition, not through engaging in Convertible Debentures. Schissler affirmed “We are focused on growing the business through organic growth, accretive acquisitions, and intelligent management, with the goal of becoming cash flow positive and continually improving the balance sheet”.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Fri Jul 13, 2007 3:32 pm

Cord Blood America, Inc. (CBAI.OB) Subsidiary’s Experienced Team and History Positions the Company to Reach Thousands of Families

Cord Blood America’s Subsidiary, CorCell, is a licensed and accredited cord blood company who has been dedicated to its work since 1995. Their stem-cell harvesting procedure is preferred by obstetricians for its safe, simple, and uncomplicated method.

The company began in Pennsylvania as the first private cord blood company licensed for umbilical cord blood collection and is now a leader in the industry. The precious stem-cells are stored in its private laboratory which is both internationally known and AABB accredited.

CorCell is focused on helping families protect future wellness, and will achieve its mission through educating and promoting the value of umbilical cord blood stem cell collection and cryopreservation to expectant families.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Sun Aug 05, 2007 1:28 pm

Cord Blood America, Inc. (CBAI.OB) is Well Established in the Stem Cell Preservation Industry

Cord Blood America is focused on becoming the most respected stem cell preservation company in the world. The company plans to achieve its goal by educating expectant parents, families with a history of disease, critically ill patients, and all others who wish to learn about their life saving service.

Through its subsidiary, CorCell, the company is a licensed and accredited cord blood company, which has been dedicated to its work since 1995. The company began in Pennsylvania as the first private cord blood company licensed for umbilical cord blood collection and today is one of the leaders in the industry.

Their stem-cell harvesting procedure is preferred by obstetricians for its safe, simple, and uncomplicated method. The precious stem-cells are stored in its private laboratory which is both internationally known and AABB accredited.

The company has demonstrated its desire to increase shareholder value and become cash flow positive by retiring registered convertible debt, in addition to lowering operational loss, increasing revenues, and halving the basic and diluted loss per share.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Wed Aug 15, 2007 7:32 am

Cord Blood America, Inc. (CBAI.OB) Reports Record Quarter Revenues

Cord Blood America announced this morning that its revenues totaled $2.346 million for the second quarter ended June 30, 2007, up 194% from the revenues in the same period in 2006. The revenues for the first six months of this year totaled $4.04 million, which is a 221% increase compared to the revenues from the first half of 2006.

The company also reported a substantial increase in its gross profit as it increased from $125,255 to $796,761. The gross profit for the first six months of 2007 totaled $1.396 million, up 1,439% compared to a gross profit of $96,641 in the first half of 2006. Net loss was decreased this year as it lowered from a 0.07 per share loss in 2006 to $0.04 a share this year.

The CEO Cord Blood America, Matthew Schissler, stated, “There were many positives in the first half of 2007 and a most important key indicator of this is gross profit, which increased from 21% of revenues to 34%. Economies of scale, especially for the Company’s Cord Blood division, started to positively impact the Company’s financial results. We intend to remain focused on our successful strategy of strategic, organic growth, accretive acquisitions and reducing overhead in the upcoming reporting periods.”

The CEO concluded, “Strong growth for the quarter, combined with a significant decrease in marketing costs, shows that the strategies we are pursuing are promoting excellent results. We are very pleased to present these financial achievements to our shareholders.”

"Please see the disclaimers on the QualityStocks.net website."

Posted: Tue Aug 21, 2007 11:56 pm

Cord Blood America (CBAI.OB) Acquires CureSource Inc.

Cord Blood America, Inc. (CBAI.OB), the umbilical cord blood stem cell preservation company announced that it has acquired the assets of CureSource, Inc., a private umbilical cord blood storage company headquartered in Charleston, South Carolina.

CureSource(TM) currently serves families throughout the U.S. "We are pleased with this transaction because Cord Blood America believes, as we do, in affordable service and taking care of the needs of the families," said CureSource Chairman Donald P. DeLuca, Sr.

Chairman and CEO Matthew Schissler said,"The CureSource transaction provides us with additional customers, and with a new territory to broaden the sales channels that the CureSource staff vigorously developed. This transaction extends Cord Blood America's geographic reach and ensures that we are one of the companies coming out on top as the industry consolidates. We view this as another major positive for our Company and our investors."

Posted: Mon Aug 27, 2007 1:24 pm

Cord Blood America, Inc. (CBAI.OB) CEO Featured in Exclusive Interview

Cord Blood America announced today that its CEO, Matthew Schissler, was featured in an interview with Francis Gaskins at StreetIQ.com. The full interview can be heard at this link: http://www.streetiq.com/mp3/gaskins/cbai20070824.mp3

In the interview, the CEO discussed Cord Blood’s recently reported financial results. For the six months ended June 30 of this year, the company announced $4.04 million in six month revenues and $1.4 million in gross profits, which the CEO was particularly pleased with as it will provide Cord Blood with additional working capital.

The interview also overviewed the company’s recent acquisition, history of growth, why CBAI.OB is undervalued, and the importance of umbilical cord blood stem cell storage.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Tue Aug 28, 2007 1:19 pm

Cord Blood America, Inc. (CBAI.OB) Continues Upward Trend, Gaining 59% this Month

CBAI.OB shares continued to increase in price today, hitting a new high for this week. The company’s recently reported strong financial performance greatly attributed to the increased shareholder value.

Cord Blood America’s acquisition of CureSource’s assets also played a part in getting the attention of investors. CureSource is known for offering affordable services to families seeking to store their umbilical cords for future medical use.

Cord Blood is committed to establishing an extraordinary track record and has been extremely successful to date. The company has accomplished many of its goals this year, which include greatly reducing operational loss, substantially increasing revenues, and significantly reducing loss per share.

"Please see the disclaimers on the QualityStocks.net website."

Posted: Wed Aug 29, 2007 8:07 am

Cord Blood America, Inc. (CBAI.OB) CEO Featured in Exclusive Interview with EquityGroups

Cord Blood America’s CEO, Matthew Schissler, was featured in an exlusive interview with Jason Buchen at EquityGroups. The entire interview can be heard at this link: http://equitygroups.com/audioint/cbai/cbai24aug.wmv

In the interview, the CEO said that investors should be increasingly interested in the stem cell sector because many more diseases will be treated and cured by stem cells. Stem cells are remarkable for their ability to develop into many different cell types, allowing them to repair damaged areas and cure diseases that were previously considered incurable.

He also said, “We are the fastest growing stem cell company that we know about, and are highly undervalued. We are positioning our Company to be in control of the inventory, which is crucial to significant corporate growth.”

"Please see the disclaimers on the QualityStocks.net website."

Posted: Mon Sep 10, 2007 9:16 am

Cord Blood America, Inc. (CBAI.OB) Share Prices Bounce Off 10-Day Moving Average – Up 5.26% Today

CBAI.OB share prices increased approximately 91% since the beginning of this month after the company announced strong performance and the acquisition of CureSource’s assets. Yesterday, the shares bounced off the 10-Day moving average and are now continuing the bullish trend.

In the press release announcing the strong financial performance, Matthew Schissler CEO of Cord Blood America, stated, “There were many positives in the first half of 2007 and a most important key indicator of this is gross profit, which increased from 21% of revenues to 34%. Economies of scale, especially for the Company’s Cord Blood division, started to positively impact the Company’s financial results. We intend to remain focused on our successful strategy of strategic, organic growth, accretive acquisitions and reducing overhead in the upcoming reporting periods.”

He concluded, “Strong growth for the quarter, combined with a significant decrease in marketing costs, shows that the strategies we are pursuing are promoting excellent results. We are very pleased to present these financial achievements to our shareholders.”

"Please see the disclaimers on the QualityStocks.net website."